The Pulse of CV Disease Management
Executive SummaryAfter years of delivering high-tech, high-cost treatments for cardiovascular disease, device companies are hard pressed to advance the cost-effective treatment arguments that drug companies have been touting in recent disease management programs. But in the cath lab, where price pressures are increasing, both ACS and SciMed are attempting a lateral entry into disease management through alliances with information systems companies.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.